Question 1

The prominent laboratory feature representative of CML is:

Accepted Answer

A)  Leukocytosis with left shift 
B)  Leukocytosis with megaloblastic anemia 
C)  Leukopenia with lymphocytosis 
D)  Leukopenia with reticulocytosis 
E)  None of the above 
A)  Leukocytosis with left shift 
B)  Leukocytosis with megaloblastic anemia 
C)  Leukopenia with lymphocytosis 
D)  Leukopenia with reticulocytosis 
E)  None of the above A

Question 2

What is the etiology of chronic myelogenous leukemia?

Accepted Answer

A)  Increased maturation in the granulocytic series 
B)  Neoplastic transformation of the hematopoietic pluripotent stem cell 
C)  Virus mediated 
D)  Suppression of myelopoiesis by cytokine 
E)  None of the above 
A)  Increased maturation in the granulocytic series 
B)  Neoplastic transformation of the hematopoietic pluripotent stem cell 
C)  Virus mediated 
D)  Suppression of myelopoiesis by cytokine 
E)  None of the above B

Question 3

Which of the following myeloproliferative disorders is characterized by a decreased LAP score?

Accepted Answer

A)  PV 
B)  IMF 
C)  ET 
D)  AML 
E)  CML 
A)  PV 
B)  IMF 
C)  ET 
D)  AML 
E)  CML E

Question 4

How is CML differentiated from a leukemoid reaction?

Accepted Answer

A)  WBC >100,000/µL 
B)  Decreased leukocyte alkaline phosphatase (LAP) 
C)  Shift to the left 
D)  Increased LAP 
E)  RBC indices 
A)  WBC >100,000/µL 
B)  Decreased leukocyte alkaline phosphatase (LAP) 
C)  Shift to the left 
D)  Increased LAP 
E)  RBC indices

Question 5

Patients with CML in blast crisis most commonly die of:

Accepted Answer

A)  Therapy related to marrow aplasia 
B)  Exsanguination 
C)  Infection 
D)  Aplasia with myelofibrosis 
E)  All of the above 
A)  Therapy related to marrow aplasia 
B)  Exsanguination 
C)  Infection 
D)  Aplasia with myelofibrosis 
E)  All of the above

Question 6

The only curative treatment for CML is __________.

Accepted Answer

A)  Steroids 
B)  Immunosuppressive drugs 
C)  Radiation therapy 
D)  Hematopoietic stem cell transplant (HSCT) 
E)  Tyrosine kinase 
A)  Steroids 
B)  Immunosuppressive drugs 
C)  Radiation therapy 
D)  Hematopoietic stem cell transplant (HSCT) 
E)  Tyrosine kinase

Question 7

What is the chromosomal abnormality in CML?

Accepted Answer

A)  t(8;14) 
B)  t(9;22) 
C)  t(1;12) 
D)  Trisomy 12 
E)  t(15;17) 
A)  t(8;14) 
B)  t(9;22) 
C)  t(1;12) 
D)  Trisomy 12 
E)  t(15;17)

Question 8

Which phase of CML carries the worst prognosis and is generally unresponsive to treatment?

Accepted Answer

A)  Chronic phase 
B)  Accelerated phase 
C)  Blast crisis 
D)  Chemotherapy-resistant phase 
E)  None of the above 
A)  Chronic phase 
B)  Accelerated phase 
C)  Blast crisis 
D)  Chemotherapy-resistant phase 
E)  None of the above

Question 9

Most patients (85%) are diagnosed in which phase of CML?

Accepted Answer

A)  Chronic 
B)  Accelerated 
C)  Blast 
D)  Remission 
E)  Refractory 
A)  Chronic 
B)  Accelerated 
C)  Blast 
D)  Remission 
E)  Refractory

Question 10

What is characteristic of the bone marrow morphology in CML?

Accepted Answer

A)  Myeloid hyperplasia 
B)  Normal M/E ratio 
C)  Myeloid hypoplasia 
D)  Hypocellularity 
E)  Erythroid hyperplasia 
A)  Myeloid hyperplasia 
B)  Normal M/E ratio 
C)  Myeloid hypoplasia 
D)  Hypocellularity 
E)  Erythroid hyperplasia

Question 11

Which chromosomal abnormality is associated with CML?

Accepted Answer

A)  Deletion 7 
B)  Chromosome 5 
C)  Trisomy 12 
D)  Philadelphia chromosome 
E)  None of the above 
A)  Deletion 7 
B)  Chromosome 5 
C)  Trisomy 12 
D)  Philadelphia chromosome 
E)  None of the above

Question 12

The usual objective of therapy for the chronic phase of CML is to:

Accepted Answer

A)  Reduce the proliferating myeloid mass 
B)  Relieve symptoms of hyperleukocytosis 
C)  Relieve symptoms of thrombocytosis 
D)  Relieve symptoms of splenomegaly 
E)  All of the above 
A)  Reduce the proliferating myeloid mass 
B)  Relieve symptoms of hyperleukocytosis 
C)  Relieve symptoms of thrombocytosis 
D)  Relieve symptoms of splenomegaly 
E)  All of the above

Question 13

Which phase of CML carries the worst prognosis and is generally unresponsive to treatment?

Accepted Answer

A)  Chronic 
B)  Accelerated 
C)  Blast 
D)  Remission 
E)  Refractory 
A)  Chronic 
B)  Accelerated 
C)  Blast 
D)  Remission 
E)  Refractory

Question 14

Philadelphia chromosome is present in __________ percent of patients with typical leukemia cells.

Accepted Answer

A)  90-95% 
B)  40-50% 
C)  40-60% 
D)  30-40% 
E)  65-75% 
A)  90-95% 
B)  40-50% 
C)  40-60% 
D)  30-40% 
E)  65-75%

Question 15

Which clinical signs are evident in CML?

Accepted Answer

A)  Splenomegaly 
B)  Hepatomegaly 
C)  Pallor 
D)  Epistaxis 
E)  All of the above 
A)  Splenomegaly 
B)  Hepatomegaly 
C)  Pallor 
D)  Epistaxis 
E)  All of the above

Question 16

All of the following are characteristics of chronic leukemias except:

Accepted Answer

A)  Insidious onset 
B)  Mature leukemia cells 
C)  Found in adults 
D)  Found primarily in children 
E)  Organomegaly 
A)  Insidious onset 
B)  Mature leukemia cells 
C)  Found in adults 
D)  Found primarily in children 
E)  Organomegaly

Question 17

When CML is diagnosed in infants and toddlers, it is called __________ CML.

Accepted Answer

A)  Young 
B)  Juvenile 
C)  Infant 
D)  Myelofibrosis 
E)  AML 
A)  Young 
B)  Juvenile 
C)  Infant 
D)  Myelofibrosis 
E)  AML

Question 18

Which of the following is not consistent with leukemoid reaction?

Accepted Answer

A)  High WBC count 
B)  High LAP 
C)  Toxic granulation of neutrophils 
D)  Presence of Philadelphia chromosome 
E)  Associated with a bacterial infection 
A)  High WBC count 
B)  High LAP 
C)  Toxic granulation of neutrophils 
D)  Presence of Philadelphia chromosome 
E)  Associated with a bacterial infection

Question 19

Chronic myelocytic leukemia (CML) is characterized by examining the production of __________ and their precursors.

Accepted Answer

A)  Erythrocytes 
B)  Platelets 
C)  Granulocytes 
D)  Lymphocytes 
E)  None of the above 
A)  Erythrocytes 
B)  Platelets 
C)  Granulocytes 
D)  Lymphocytes 
E)  None of the above

Question 20

CML can be differentiated from polycythemia vera, essential thrombocythemia, and agnogenic myeloid metaplasia by the presence of __________.

Accepted Answer

A)  Leukocytosis 
B)  Ph chromosome 
C)  Splenomegaly 
D)  Erythrocytosis 
E)  Thrombocytosis 
A)  Leukocytosis 
B)  Ph chromosome 
C)  Splenomegaly 
D)  Erythrocytosis 
E)  Thrombocytosis

Exam 17: Chronic Myeloproliferative Disorders I: Chronic Myelogenous Leukemia

The prominent laboratory feature representative of CML is:

What is the etiology of chronic myelogenous leukemia?

Which of the following myeloproliferative disorders is characterized by a decreased LAP score?

How is CML differentiated from a leukemoid reaction?

Patients with CML in blast crisis most commonly die of:

The only curative treatment for CML is __________.

What is the chromosomal abnormality in CML?

Which phase of CML carries the worst prognosis and is generally unresponsive to treatment?

Most patients (85%) are diagnosed in which phase of CML?

What is characteristic of the bone marrow morphology in CML?

Which chromosomal abnormality is associated with CML?

The usual objective of therapy for the chronic phase of CML is to:

Which phase of CML carries the worst prognosis and is generally unresponsive to treatment?

Philadelphia chromosome is present in __________ percent of patients with typical leukemia cells.

Which clinical signs are evident in CML?

All of the following are characteristics of chronic leukemias except:

When CML is diagnosed in infants and toddlers, it is called __________ CML.

Which of the following is not consistent with leukemoid reaction?

Chronic myelocytic leukemia (CML) is characterized by examining the production of __________ and their precursors.

CML can be differentiated from polycythemia vera, essential thrombocythemia, and agnogenic myeloid metaplasia by the presence of __________.

Morphology of Human Blood and Marrow Cells: Hematopoiesis

Bone Marrow

The Red Blood Cell: Structure and Function

Anemia: Diagnosis and Clinical Considerations

Evaluation of Red Blood Cell Morphology and Introduction to Platelet and White Blood Cell Morphology

Iron Metabolism and Hypochromic Anemias

Megaloblastic Anemias

Aplastic Anemia Including Pure Red Cell Aplasia and Congenital Dyserythropoietic Anemia and Paroxysmal Nocturnal Hemoglobinuria

Introduction to Hemolytic Anemias: Intracorpuscular Defects: I Hereditary Defects of the Red Cell Membrane

Hemolytic Anemias: Intracorpuscular Defects: II Hereditary Enzyme Deficiencies

Hemolytic Anemias: Intracorpuscular Defects: III the Hemoglobinopathies

Hemolytic Anemias: Intracorpuscular Defects: Iv Thalassemia

Hemolytic Anemias: Extracorpuscular Defects

Hypoproliferative Anemia: Anemia Associated With Systemic Diseases

Cell Biology, Disorders of Neutrophils, Infectious Mononucleosis, and Reactive Lymphocytosis

Introduction to Leukemia and the Acute Leukemias

Chronic Myeloproliferative Disorders Ii: Polycythemia Vera, Essential Thrombocythemia, and Idiopathic Myelofibrosis

Myelodysplastic Syndromes

Chronic Lymphocytic Leukemia and Related Lymphoproliferative Disorders

The Lymphomas

Multiple Myeloma and Related Plasma Cell Disorders

Lipid Lysosomal Storage Diseases and Histiocytosis

Introduction to Hemostasis

Disorders of Primary Hemostasis: Quantitative and Qualitative Platelet Disorders and Vascular Disorders

Disorders of Plasma Clotting Factors

Interaction of the Fibrinolytic, Coagulation, and Kinin Systems; Disseminated Intravascular Coagulation; and Related Pathology

Introduction to Thrombosis and Anticoagulant Therapy

Quality Control in the Hematology Laboratory

Body Fluid Examination: the Qualitative, Quantitative, and Morphologic Analysis of Serous, Cerebrospinal, and Synovial Fluids

Hematology Methods

Principles of Automated Differential Analysis

Coagulation Procedures

Applications of Flow Cytometry to Hematology and Hemostasis

Molecular Diagnostic Techniques in Hematopathology

Special Stainscytochemistry

Filters